Published in final edited form as:

Bioorg Med Chem. 2013 June 15; 21(12): 3597–3601. doi:10.1016/j.bmc.2013.04.057.

Bioavailable affinity label for collagen prolyl 4-hydroxylase

James D. Vasta^a, Joshua J. Higgin^b, Elizabeth A. Kersteen^a, and Ronald T. Raines^{a,b}

^aDepartment of Biochemistry, University of Wisconsin–Madison, 433 Babcock Drive, Madison, Wisconsin 53706-1544, USA

^bDepartment of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, Wisconsin 53706-1322, USA

Abstract

Collagen is the most abundant protein in animals. Its prevalent 4-hydroxyproline residues contribute greatly to its conformational stability. The hydroxyl groups arise from a post-translational modification catalyzed by the non-heme iron-dependent enzyme, collagen prolyl 4-hydroxylase (P4H). Here, we report that 4-oxo-5,6-epoxyhexanoate, a mimic of the α -ketoglutarate co-substrate, inactivates human P4H. The inactivation installs a ketone functionality in P4H, providing a handle for proteomic experiments. *Caenorhabditis elegans* exposed to the esterified epoxy ketone displays the phenotype of a worm lacking P4H. Thus, this affinity label can be used to mediate collagen stability in an animal, as is desirable in the treatment of a variety of fibrotic diseases.

Keywords

affinity label; α -ketoglutarate; *Caenorhabditis elegans*; collagen; prolyl 4-hydroxylase

1. Introduction

Collagen is the most abundant protein in animals, and maintains the structural integrity of various connective tissues.¹ The overproduction of collagen is associated with fibrotic diseases, including myocardial infarction, stroke, peripheral vascular disease, diabetes, and severe anemias.² The stability of collagen relies on catalysis by collagen prolyl 4-hydroxylase (P4H).³ This enzyme is located in the lumen of the endoplasmic reticulum, where it catalyzes a remarkable post-translational modification—the conversion of (2*S*)-proline residues (Pro) to (2*S*,4*R*)-4-hydroxyproline residues (Hyp) in protocollagen strands. The human enzyme consists of an $\alpha_2\beta_2$ tetramer in which each α subunit contains an active site. P4H is essential for animals,^{4–6} as the conformational stability of mature collagen relies on its hydroxylation.^{7–9} Moreover, P4H is a validated target for the treatment of fibrotic diseases.²

© 2013 Elsevier Ltd. All rights reserved.

Correspondence to: Ronald T. Raines.

This paper is dedicated to Professor Ashraf Brik on the occasion of his winning the 2013 Tetrahedron Young Investigator Award in Bioorganic & Medicinal Chemistry.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

P4H is a non-heme iron(II) dioxygenase that uses O₂ α -ketoglutarate as co-substrates (Figure 1A). The three-dimensional structure of mammalian P4H is unknown. We reasoned that an electrophilic analog of α -ketoglutarate could serve as an irreversible inhibitor of the enzyme and, hence, a useful probe for active-site residues. Inspired by natural products such as trapoxin and epolactaene as well as artificial affinity labels,¹⁰ we designed 4-oxo-5,6-epoxyhexanoate (**1**) for this purpose. Our thought was that the epoxide oxygen would chelate to the active-site iron and thereby be activated for nucleophilic attack (Figure 1B). We also noted that α -ketoglutarate and epoxy ketone **1** have the same number and a similar arrangement of non-hydrogen atoms. This attribute is important because of the inability of larger α -ketoglutarate analogs to inhibit catalysis by human P4H.¹¹ Epoxy ketone **1**, which also resembles 5-aminolevulinic acid, is a known competitive inhibitor of 5-aminolevulinic acid dehydratase but does not alkylate that enzyme.¹³

2. Results and discussion

2.1. Effect of epoxy ketone **1** on catalysis by P4H

We produced human P4H by heterologous expression in *Escherichia coli*,^{14–18} and we synthesized racemic **1**. We assayed the effect of this putative affinity label on the ability of P4H to catalyze the hydroxylation of a fluorescent peptidic substrate, dansyl-Gly-Phe-Pro-Gly-OEt.^{14–17} The data revealed that epoxy ketone **1** elicits irreversible inactivation of P4H, and does so in a concentration-dependent manner (Figure 2A). α -Ketoglutarate protected P4H against inactivation (Figure 2B), suggesting that epoxy ketone **1** competes with this co-substrate for binding to the active site.

2.2. Utility of epoxy ketone **1** as a proteomic probe

Noting that a ketone has chemical reactivity orthogonal to that in natural amino acids,²⁰ we examined the utility of epoxy ketone **1** in a model proteomic experiment. Epoxy ketone **1** was incubated with P4H in the presence of iron(II). The mixture was treated with biocytin hydrazide and then NaBH₄ to reduce the incipient *N*-acyl hydrazone (which is unstable²¹). Small molecules were removed by gel-filtration chromatography. The P4H was added to wells of a microplate containing immobilized streptavidin. The wells were washed and exposed to a monoclonal antibody directed against P4H. Visualization with a secondary antibody conjugated to horseradish peroxidase revealed that P4H is associated with streptavidin only in the presence of epoxy ketone **1** (Figure 2C). The conjugation was confirmed by SDS-PAGE (data not shown). These data indicate that epoxy ketone **1** could serve as a chemoselective probe for P4H. Thus, epoxy ketone **1** complements a (2*S*,4*S*)-4-fluoroproline substrate that spawns a ketone upon P4H catalysis.¹⁶

2.3. Effect of epoxy ketone **1** on an animal

Finally, we determined the effect of epoxy ketone **1** on a live animal. Like all animals (including dinosaurs²²), *Caenorhabditis elegans* has an abundance of collagen. In wild-type worms, P4H exists largely as a tetramer of two α subunits (DPY-18 and PHY-2, which each contain an active site) and two β subunits.²³ The *dpy-18* gene is essential for body morphology, whereas the function of the *phy-2* gene is not apparent.^{4,5} The deletion of both genes results in embryos that grow to the twofold stage, but are unable to maintain their shape and consequently explode.⁵ These two forms of the α subunit have 56.5% amino-acid sequence identity with each other and ~50% identity with their human homologues. α -Ketoglutarate analogs can eliminate the remaining P4H activity in *dpy-18 C. elegans* at concentrations that do not affect the wild-type worm.⁵ This synthetic lethality provided the basis for our assay.

Dpy-18 worms were placed onto solid medium containing known concentrations of esterified epoxy ketone **1**. The ester group, which can be hydrolyzed by cellular esterases, served to mask the anionic carboxylate and thus enhance uptake.^{5,24} Concentration-dependent embryonic lethality of *dpy-18 C. elegans* was observed with LD₅₀ = 0.11 mM (Figure 3). These data are consistent with lethality being due to P4H inactivation.

3. Conclusion

The need for small-molecule probes and inhibitors of P4H is evident from the lack of structural information about this essential enzyme as well as the list of fibrotic diseases associated with collagen overproduction.² The newly discovered role of P4Hs in hypoxia^{25–27} and cancer,²⁸ and the cardioprotection conferred by P4H inhibitors^{29–31} increase the imperative.³² Our identification of 4-oxo-5,6-epoxyhexanoate as an affinity label for P4H that is bioavailable upon esterification provides a means to address this need. On-going efforts in our laboratory are directed at identifying the alkylated enzymic residue, improving the potency of the epoxy ketone as an affinity label, and evaluating its selectivity towards other P4Hs.

4. Experimental procedures

4.1. General

BakerDry™ solvents in cycloainers™ (DMF, 20 ppm water; CH₂Cl₂, 30 ppm water; THF, 10 ppm water) were from J. T. Baker (Phillipsburg, NJ). Unless noted otherwise, all other chemicals were from Aldrich Chemical (Milwaukee, WI), Fisher Scientific (Pittsburgh, PA), or NovaBiochem (San Diego, CA), and were used without further purification.

Human collagen prolyl 4-hydroxylase (P4H) was produced in *E. coli* and purified as described previously.^{14–18} Dansyl-Gly-Phe-Pro-Gly-OEt, a fluorescent P4H substrate, was synthesized as described previously.^{14–17}

In the synthetic procedures, the term “concentrated under reduced pressure” refers to the removal of solvents and other volatile materials using a rotary evaporator at water aspirator pressure (<20 torr) while maintaining the water-bath temperature below 50 °C.

4.2. Instrumentation

NMR spectra were obtained with a Bruker AC+ 300 MHz, Bruker DMX 400 WB, or Bruker Avance III 500i spectrometer. Mass spectra were obtained with a Micromass LCT® electrospray ionization, time-of-flight analyzer from Waters (Milford, MA). HPLC analyses were performed with an instrument from Waters controlled with the Millenium (version 3.20) software package and equipped with two 515 pumps, a 717plus autosampler, and a 996 photodiode array detector.

4.3. Synthesis of 4-oxo-5,6-epoxyhexanoate (1)

Epoxy ketone **1** was synthesized in 5 steps with an overall yield of 38% by the route shown in Scheme 1 and described below.

4.3.1. Benzyl succinic acid (2)—Benzyl succinic acid was synthesized by following a known procedure.³³ Here, succinic anhydride (30 g, 300 mmol) was dissolved in benzyl alcohol (31.6 mL, 33 g, 300 mmol), and the resulting solution was heated at reflux for 4 h. The reaction mixture was dissolved in ether (100 mL), and the insoluble succinic acid was removed by filtration. The filtrate was extracted with saturated aqueous Na₂CO₃ (3 × 100

mL), and the combined aqueous extracts were acidified with 2 M HCl (2.0 L). The precipitate was collected by filtration and dried under vacuum to give **2** (30 g, 48%). ¹H NMR (CDCl₃, 300 MHz) δ 7.35 (m, 5H), 5.15 (s, 2H), 2.70 (m, 4H). ¹³C NMR (CDCl₃, 75 MHz) δ 177.7, 172.1, 135.7, 128.8, 128.5, 128.4, 66.9, 29.1, 29.0.

4.3.2. Benzyl 4-Chlorooxobutyrate (3)—Benzyl 4-chlorooxobutyrate was synthesized by following a known procedure.³⁴ Here, benzyl succinic acid (4.14 g, 20 mmol) was dissolved in CH₂Cl₂ (150 mL), and the resulting solution was cooled to 0 °C. Oxalyl chloride (13.8 g, 109 mmol) was added slowly, and the reaction mixture was stirred at 0 °C for 5 min. The reaction mixture was allowed to warm to 15 °C and stirred for an additional 30 min. The reaction mixture was then concentrated under reduced pressure, and the residue was dissolved in benzene. The residue was concentrated under reduced pressure to give **3** (4.5 g, 99%) as a clear viscous liquid. ¹H NMR (CDCl₃, 300 MHz) δ 7.34 (m, 5H), 5.13 (s, 2H), 3.19 (t, *J* = 7 Hz, 2H), 2.69 (t, *J* = 7 Hz, 2H). ¹³C NMR (CDCl₃, 75 MHz) δ 173.2, 170.9, 135.6, 128.8, 128.6, 128.4, 67.1, 29.5, 28.5.

4.3.3. Benzyl 4-Oxo-5-hexenoate (4)—Benzyl 4-oxo-5-hexenoate (**4**) was synthesized in 82% yield from benzyl 4-chlorooxobutyrate in the same manner as was ethyl 4-oxo-5-hexenoate (**6**) from ethyl 4-chlorooxobutyrate, *vide infra*. ¹H NMR (CDCl₃, 300 MHz) δ 7.35 (m, 5H), 6.38 (dd, *J* = 10 and 18 Hz, 1H), 6.26 (dd, *J* = 1 and 18 Hz, 1H), 5.86 (dd, *J* = 1 and 10 Hz, 1H), 5.13 (s, 2H), 2.94 (t, *J* = 7 Hz, 2H), 2.70 (t, *J* = 7 Hz, 2H).

4.3.4. Benzyl 4-oxo-5,6-epoxyhexanoate (5)—Benzyl 4-oxo-5,6-epoxyhexanoate (**5**) was synthesized in 98% yield from benzyl 4-oxo-5-hexenoate in the same manner as was ethyl 4-oxo-5,6-epoxyhexanoate (**6**) from ethyl 4-oxo-5-hexenoate (**7**), *vide infra*. ¹H NMR (CDCl₃, 300 MHz) δ 7.34 (m, 5H), 5.10 (s, 2H), 3.46 (dd, *J* = 2 and 5 Hz, 1H), 2.99 (dd, *J* = 5 and 6 Hz, 1H), 2.94 (dd, *J* = 2 and 6 Hz, 1H), 2.64 (m, 4H). ¹³C NMR (CDCl₃, 75 MHz) δ 206.1, 172.4, 135.9, 128.7, 128.5, 128.4, 66.6, 53.7, 46.3, 31.3, 27.5.

4.3.5. 4-Oxo-5,6-epoxyhexanoic acid (1, free acid)—Benzyl 4-oxo-5,6-epoxyhexanoate (340 mg, 1.45 mmol) was dissolved in EtOAc (20 mL). Pd/C (10% w/w, 40 mg) was added, and the reaction mixture was stirred under H₂(g) for 4 h. The reaction mixture was filtered through Celite®, and concentrated under reduced pressure to give the free acid of epoxy ketone **1** (183 mg, 99%). ESI MS EMM *m/z*: [M – H][–] 143.0340, calcd. 143.0344. ¹H NMR (CDCl₃, 300 MHz) δ 10.74 (br s, 1H), 3.48 (dd, *J* = 2 and 5 Hz, 1H), 3.03 (dd, *J* = 5 and 5 Hz, 1H), 2.96 (dd, *J* = 2 and 5 Hz, 1H), 2.64 (m, 4H). ¹³C NMR (CDCl₃ 75 MHz) δ 206.1, 178.3, 53.7, 46.4, 31.1, 27.2.

4.3.6. Sodium 4-oxo-5,6-epoxyhexanoate (1, sodium salt)—4-Oxo-5,6-epoxyhexanoic acid (206 mg, 1.4 mmol) was dissolved in aqueous NaHCO₃ (3.6 mL, 400 mM), and the resulting solution was stirred for 1 h. The reaction mixture was concentrated to dryness by lyophilization to give the water-soluble sodium salt of epoxy ketone **1** (237 mg, quant), which was used for assays *in vitro*. ¹H NMR (D₂O, 500 MHz) δ 3.69 (dd, *J* = 3 and 5 Hz, 1H), 3.00 (t, *J* = 5 and 6 Hz, 1H), 2.80 (dd, *J* = 3 and 6 Hz, 1H), 2.70 (m, 2H), 2.34 (t, *J* = 7 Hz, 2H). ¹³C NMR (D₂O, 125 MHz) δ 211.7, 182.1, 54.2, 48.7, 36.1, 31.5.

4.4. Synthesis of ethyl 4-oxo-5,6-epoxy-hexanoate (6, esterified 1)

Esterified **1** was synthesized in 2 steps with an overall yield of 70% by the route shown in Scheme 2 and described below.

4.4.1. Ethyl 4-oxo-5-hexenoate (7)—Ethyl 4-oxo-5-hexenoate was synthesized by following a known procedure.³⁵ Here, ethyl 4-chlorooxobutyrate (2.5 g, 15.2 mmol) was

dissolved in HMPA (10 mL). Tributylvinyltin (5.0 g, 15.2 mmol) and benzylchlorotriphenylphosphine palladium(II) (52 mg) were added, and the reaction mixture was heated open to air to 65 °C for 5 min. At that time, the reaction mixture turned black. The reaction mixture was allowed to cool to room temperature. H₂O (50 mL) and NaCl (1.0 g) were added, and the resulting solution was stirred for 5 min. The solution was extracted with diethyl ether (3 × 60 mL). The combined organic extracts were washed with H₂O (4 × 60 mL), and the organic layer was dried over MgSO₄(s) and concentrated under reduced pressure to ~20 mL. A half-saturated solution of KF in MeOH (25 mL) was added to precipitate the SnBu₃F, which was removed by filtration through Celite®. The filtrate was concentrated under reduced pressure and purified by chromatography on silica gel, eluting with ethyl acetate (10% v/v) in CH₂Cl₂ to give **7** (1.944 g, 82%). ESI MS *m/z*: [M + Na]⁺ 179.0, calcd 179.1. ¹H NMR (CDCl₃, 400 MHz) δ 6.35 (dd, *J* = 10 and 18 Hz, 1H), 6.23 (dd, *J* = 1 and 18 Hz, 1H), 5.84 (dd, *J* = 1 and 10 Hz, 1H), 4.10 (q, *J* = 7 Hz, 2H), 2.89 (t, *J* = 7 Hz, 2H), 2.59 (t, *J* = 7 Hz, 2H), 1.21 (t, *J* = 7, 3H). ¹³C NMR (CDCl₃, 100 MHz) δ 198.5, 172.7, 136.2, 128.4, 60.6, 34.0, 27.9, 14.1.

4.4.2. Ethyl 4-oxo-5,6-epoxy-hexanoate—Ethyl 4-oxo-5,6-epoxyhexanoate was synthesized by following a known procedure.¹³ Here, ethyl 4-oxo-5-hexenoate (1.107 g, 7.09 mmol) and H₂O₂ (30% v/v, 1.75 mL) were dissolved in *t*BuOH (11.81 mL) and H₂O (5.9 mL) at 0 °C. Saturated aqueous K₂CO₃ (606 μL) at 0 °C was added slowly. The reaction mixture was stirred for 1 h at 0 °C, allowed to warm to room temperature, and then stirred for an additional 3 h. The reaction mixture was diluted with H₂O (100 mL) and extracted with diethyl ether (3 × 30 mL). The combined organic extracts were dried over MgSO₄(s) and concentrated under reduced pressure. The product was purified by chromatography on silica gel, eluting with ethyl acetate (10% v/v) in CH₂Cl₂ to give **6** (1.04 g, 85%). ESI MS *m/z*: [M + Na]⁺ 195.0, calcd 195.1. ¹H NMR (CDCl₃, 300 MHz) δ 4.11 (q, *J* = 7 Hz, 2H), 3.48 (dd, *J* = 3 and 4 Hz, 1H), 3.03 (dd, *J* = 4 and 6 Hz, 1H), 3.01 (dd, *J* = 3 and 6 Hz, 1H), 2.66 (m, 4H), 1.25 (t, *J* = 7 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ 206.3, 172.6, 60.9, 53.7, 46.3, 31.3, 27.5, 14.3.

4.5. *In vitro* assay of P4H activity

The enzymatic activity of P4H was assayed as described previously.¹⁴ Briefly, substrate (dansyl-Gly-Phe-Pro-Gly-OEt) was added to 1 mL of 50 mM Tris-HCl buffer, pH 7.8, containing P4H (0.43 μM), FeSO₄ (0.1 mM), BSA (1 mg/mL), catalase (0.1 mg/mL), ascorbate (2 mM), DTT (0.1 mM), and α-ketoglutarate (0.5 mM). Aliquots (30 μL) were removed at 60, 180, and 300 s, quenched by boiling for 30 s, and injected onto a Microsorb-MV C18 reversed-phase HPLC column (4.6 × 250 mm, 100-Å pore size) from Varian (Palo Alto, CA). The column was eluted at 1 mL/min with aqueous acetonitrile (50% v/v), and the absorbance of the eluent was monitored at 337.5 nm. All assays were performed in triplicate.

4.6. *In vitro* assay for irreversible inhibition of P4H

P4H (43 μM) was incubated for 2.5, 5, 10, or 15 min with FeSO₄ (2 mM) and epoxy ketone **1** in 50 mM Tris-HCl buffer, pH 7.8. BSA (1 mg/mL), catalase (0.1 mg/mL), ascorbate (2 mM), DTT (0.1 mM), and α-ketoglutarate (0.5 mM) were added to this reaction mixture. Substrate (dansyl-Gly-Phe-Pro-Gly-OEt) was added to initiate the reaction, and assays for P4H activity were performed as described above. All assays were performed in triplicate. Data are reported as activity relative to control reaction mixtures that lacked epoxy ketone **1**. Half-times for inactivation at various inhibitor concentrations are determined from linear least-squares regression analysis of the log of the relative rates. Half-times for inactivation were plotted against the reciprocal of inhibitor concentration in a Kitz-Wilson plot¹⁹ to determine the value of k_{inact}/K_i .

4.7. Protection of P4H by α -ketoglutarate

Epoxy ketone **1** (356 mM), P4H (43 μ M), and FeSO₄ (2 mM) were incubated for 5 min with α -ketoglutarate (0, 15, 30, or 50 mM) in 50 mM Tris-HCl buffer, pH 7.8. BSA (1 mg/mL), catalase (0.1 mg/mL), ascorbate (2 mM), DTT (0.1 mM), and substrate (dansyl-Gly-Phe-Pro-Gly-OEt) (2.5 mM) were added to initiate the reaction. Aliquots were removed at 15, 60, 120, 180, 240, and 300 s, quenched by boiling for 30 s, and injected onto the C18 reversed-phase HPLC column described above. The column was eluted at 1 mL/min with aqueous acetonitrile (50% v/v), and the absorbance of the eluent was monitored at 337.5 nm. Reaction rates were compared to the reactions without inhibitor.

4.8. Immobilization of P4H

P4H (50 μ g) was incubated for 30 min at 37 °C with FeSO₄ (0.1 mM), ascorbate (5 mM), and epoxy ketone **1** (13 mM) in 1 mL of PBS. Biocytin hydrazide was added (to 11 mM), and the reaction mixture was incubated for an additional 30 min at 37 °C. NaBH₄ (30 mg/mL in 10 mM NaOH) was added to the reaction mixture to reduce the acylhydrazone. The P4H complex was desalted using a NICKTM column from Amersham Pharmacia (Uppsala, Sweden) and incubated on Reacti-BindTM streptavidin coated microtiter plates from Pierce Chemical (Rockford, IL) for 1 h at 37 °C. The wells were washed (4 $\times$) with blocking buffer (0.1% w/v BSA and 0.05% v/v Tween 20[®] in PBS). A mouse monoclonal antibody specific to the α -subunit of human P4H (ICN Biomedicals, Costa Mesa, CA) was added to the wells, and incubated for 1 h at 37 °C. The wells were washed again (4 $\times$) with blocking buffer. Anti-mouse IgG-peroxidase conjugate from Sigma Chemical (St. Louis, MO) was added to the wells, and the plate was incubated for 1 h at 37 °C. The wells were washed again (4 $\times$) with blocking buffer. *O*-Phenylenediamine solution (0.05 M citric acid/0.05 M sodium phosphate buffer, pH 5.0, containing 1 mg/mL *O*-phenylenediamine and 0.003% v/v H₂O₂) was added to the wells, and catalysis of *O*-phenylenediamine oxidation by peroxidase was monitored at 490 nm after quenching the reaction with H₂SO₄ (2.5 M).

4.9. *In vivo* assay of epoxy ketone **1**

The effect of epoxy ketone **1** on *dpy-18 Caenorhabditis elegans* was assayed by modification of a known procedure.⁵ Here, **6** (esterified **1**) in DMSO was added to a plate containing solid growth medium (4 mL), which consisted of agar (17 g/L), Bacto-Peptone (2.5 g/L), NaCl (50 mM), cholesterol (5 mg/L), CaCl₂ (1 mM), and MgSO₄ (1 mM) in 1 mM potassium phosphate buffer, pH 6.³⁶ The inhibitor was allowed to diffuse throughout the agar for 24 h. Four L4 worms were then added to each plate. After sufficient time for the L4 worms to grow to adult stage and lay eggs (24–48 h), the adult worms were removed to simplify counting. After sufficient time for all live eggs to hatch into worms (24 h), live worms and dead embryos (typically, 40–100) were counted by using a light microscope.

Acknowledgments

We are grateful to Drs. Katrina H. Jensen and Lisa Friedman for guidance with chemical synthesis and *in vivo* assays, respectively. This work was supported by Grant R01 AR044276 (NIH). J.D.V. was supported by Molecular Biosciences Training Grant T32 GM007215 (NIH). E.A.K. was supported by Biotechnology Training Grant T32 GM083149 (NIH). The Micromass LCT[®] mass spectrometer was purchased with funds from Grant CHE-9974839 (NSF). This study made use of the National Magnetic Resonance Facility at Madison, which was supported by Grants P41 RR002301 and P41 GM066326 (NIH). Additional NMR equipment was purchased with funds from the University of Wisconsin, the NIH (RR 002781, RR 008438), the NSF (DMB-8415048, OIA-9977486, BIR-9214394), and the USDA.

References and notes

1. Shoulders MD, Raines RT. *Annu. Rev. Biochem.* 2009; 78:929–958. [PubMed: 19344236]

2. Myllyharju J. *Ann. Med.* 2008; 40:402–417. [PubMed: 19160570]
3. Gorres KL, Raines RT. *Crit. Rev. Biochem. Mol. Biol.* 2010; 45:106–124. [PubMed: 20199358]
4. Winter AD, Page AP. *Mol. Cell. Biol.* 2000; 20:4084–4093. [PubMed: 10805750]
5. Friedman L, Higgin JJ, Moulder G, Barstead R, Raines RT, Kimble J. *Proc. Natl. Acad. Sci. USA.* 2000; 97:4736–4741. [PubMed: 10781079]
6. Holster T, Pakkanen O, Soininen R, Sormunen R, Nokelainen M, Kivirikko KI, Myllyharju J. *J. Biol. Chem.* 2007; 282:2512–2519. [PubMed: 17135260]
7. Berg RA, Prockop DJ. *Biochem. Biophys. Res. Commun.* 1973; 52:115–120. [PubMed: 4712181]
8. Rosenbloom J, Harsch M, Jimenez S. *Arch. Biochem. Biophys.* 1973; 158:478–484. [PubMed: 4592982]
9. Burjanadze TV. *Biopolymers.* 2000; 53:523–528. [PubMed: 10775067]
10. Cravatt BF, Wright AT, Kozarich JW. *Annu. Rev. Biochem.* 2008; 77:383–414. [PubMed: 18366325]
11. Higgin, JJ. Ph.D. Thesis. University of Wisconsin–Madison; 2004.
12. Laurent C. *Tetrahedron: Asymmetry.* 2001; 12:2359–2383.
13. Appleton D, Duguid AB, Lee S-K, Ha Y-J, Ha H-J, Leeper FJ. *J. Chem. Soc., Perkin Trans. 1.* 1998:89–101.
14. Kersteen EA, Higgin JJ, Raines RT. *Protein Exp. Purif.* 2004; 38:279–291.
15. Gorres KL, Edupuganti R, Krow GR, Raines RT. *Biochemistry.* 2008; 47:9447–9455. [PubMed: 18702512]
16. Gorres KL, Raines RT. *Anal. Biochem.* 2009; 386:181–185. [PubMed: 19111518]
17. Gorres KL, Pua KH, Raines RT. *PLoS One.* 2009; 4:e7635. [PubMed: 19890397]
18. Pinkas DM, Ding S, Raines RT, Barron AE. *ACS Chem. Biol.* 2011; 15:320–324. [PubMed: 21210682]
19. Kitz R, Wilson IB. *J. Biol. Chem.* 1962; 237:3245–3249. [PubMed: 14033211]
20. Zhang Z, Smith BA, Wang L, Brock A, Cho C, Schultz PG. *Biochemistry.* 2003; 42:6735–6746. [PubMed: 12779328]
21. Kalia J, Raines RT. *Angew. Chem. Int. Ed.* 2008; 47:7253–7256.
22. Schweitzer MH, Zheng W, Organ CL, Avci R, Suo Z, Freimark LM, Lebleu VS, Duncan MB, Vander Heiden MG, Neveu JM, Lane WS, Cottrell JS, Horner JR, Cantley LC, Kalluri R, Asara JM. *Science.* 2009; 324:626–631. [PubMed: 19407199]
23. Myllyharju J, Kukkola L, Winter AD, Page AP. *J. Biol. Chem.* 2002; 277:29187–29196. [PubMed: 12036960]
24. Testa, B.; Mayer, JM. *Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology.* New York, NY: Academic Press; 2003.
25. Kaelin WG Jr, Ratcliffe PJ. *Mol. Cell.* 2008; 30:393–402. [PubMed: 18498744]
26. Chowdhury R, Hardy A, Schofield CJ. *Chem. Soc. Rev.* 2008; 37:1308–1309. [PubMed: 18568157]
27. Fraisl P, Aragonés J, Carmeliet P. *Nat. Rev. Drug Discov.* 2009; 8:139–152. [PubMed: 19165233]
28. Kaelin WG Jr. *Cold Spring Harb. Symp. Quant. Biol.* 2011; 76:335–345. [PubMed: 22089927]
29. Wright G, Higgin JJ, Raines RT, Steenbergen C, Murphy E. *J. Biol. Chem.* 2003; 278:20235–20239. [PubMed: 12649278]
30. Ong SG, Hausenloy DJ. *Pharmacol. Ther.* 2012; 136:69–81. [PubMed: 22800800]
31. Sen Banerjee S, Thirunavukkarasu M, Tipu Rishi M, Sanchez JA, Maulik N, Maulik G. *Toxicol. Mech. Methods.* 2012; 22:347–358. [PubMed: 22424133]
32. Rose NR, McDonough MA, King ONF, Kawamura A, Schofield CJ. *Chem. Soc. Rev.* 2011; 40:4364–4397. [PubMed: 21390379]
33. Linstead RP, Weedon BCL, Wladislaw B. *J. Chem. Soc.* 1955:1097–1100.
34. Abell AD, Morris KB, Litten JC. *J. Org. Chem.* 1990; 55:5217–5221.
35. Milstein D, Stille JK. *J. Org. Chem.* 1979; 44:1613–1618.

36. Hope, IA. A Practical Approach. elegans, C., editor. Oxford; New York: Oxford University Press; 1999.

A **B** **Figure 1.**

(A) Reaction catalyzed by prolyl 4-hydroxylase. (B) Notional image of α -ketoglutarate (left) or epoxy ketone **1** (right) bound in the active site of P4H and interacting with an enzymic base, B. Alkylation is more likely to occur by nucleophilic attack at C6 than C5.¹²

Figure 2.

In vitro assays of epoxy ketone **1**. (A) Kitz–Wilson plot¹⁹ showing the effect of different concentrations of epoxy ketone **1** on the catalytic activity of P4H. $k_{\text{inact}}/K_i = 0.09 \text{ M}^{-1}\text{s}^{-1}$. Inset: Raw data. (B) Effect of α -ketoglutarate concentration on the inactivation of P4H by epoxy ketone **1**. (C) Immobilization of P4H after its reaction with epoxy ketone **1**. Wells 1 and 2, $A_{490} = 0.14$; wells 3 and 4, $A_{490} = 0.98$.

Figure 3.

In vivo assay of epoxy ketone **1**. *Dpy-18 C. elegans* worms (four in stage L4) were exposed to known concentrations of epoxy ketone **1** in the growth medium. Lethality refers to eggs that do not hatch. Insets: Image of lethality observed in the embryos of either a *dpy-18/phy-2* animal or a *dpy-18* animal exposed to epoxy ketone **1** (top); image of an adult *dpy-18* animal not exposed to epoxy ketone **1** (bottom).

Scheme 1.
Route for the synthesis of epoxy ketone **1**.

Scheme 2.
Route for the synthesis of **6** (esterified **1**).